Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.38 |
| ▸ | GPR6 | P46095 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.36 |
| ▸ | HTR3B | O95264 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23611767 | 0.91 | TP53 (0.42) | LMNATP53NTRK1MAPTTHRB | |
| SCHEMBL23623309 | 0.91 | ALOX15 (0.43) | LMNATP53MAPTTHRBPOLB | |
| SCHEMBL23623267 | 0.90 | TP53 (0.42) | LMNATP53NTRK1MAPTTHRB | |
| SCHEMBL23623602 | 0.88 | NAMPT (0.40) | NAMPTLMNATP53GPR6KCNH2 | |
| SCHEMBL23611738 | 0.86 | ALOX15 (0.44) | LMNATP53NTRK1MAPTTHRB | |
| SCHEMBL23623328 | 0.85 | LMNA (0.38) | LMNATP53NTRK1GPR6MAPT | |
| SCHEMBL29930983 | 0.84 | LMNA (0.44) | LMNATP53GPR6KCNH2GRIN2B | |
| SCHEMBL23611715 | 0.84 | LMNA (0.44) | LMNATP53GPR6KCNH2GRIN2B | |
| SCHEMBL23611766 | 0.83 | CTSA (0.38) | LMNATP53NTRK1MAPTTHRB | |
| SCHEMBL23611711 | 0.82 | ADORA3 (0.41) | LMNATP53MAPTTHRBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023091590-A1 | COMPOUNDS FOR USE IN TREATING GASTRIC CANCER | BERG LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2022-01-06 | — | — | US | disclosed |
| US-11091447-B2 | UBE2K modulators and methods for their use | BERG LLC (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210214320-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2021-07-15 | — | — | US | disclosed |
| WO-2021138540-A1 | POLYCYCLIC AMIDES AS UBE2K MODULATORS FOR TREATING CANCER | BERG LLC (US) | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091447-B2 | UBE2K modulators and methods for their use | UBE2N, UBE2B, UBE2E1 | NAMPT 3520/4885LMNA 3530/4885TP53 896/4885 |
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | UBE2N, UBE2B, UBE2E1 | NAMPT 3520/4885LMNA 3530/4885TP53 896/4885 |
| US-20210214320-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | UBE2N, UBE2B, UBE2E1 | NAMPT 3520/4885LMNA 3530/4885TP53 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.